Hepatitis C



Hepatitis c and Vitamin D and Iron Status


Condition:   Hepatitis C
Interventions:   Drug: Sofosbuvir 400 mg;   Drug: Daclatasvir 60 mg/day
Sponsor:   Eman Sayed Hassan Abd Allah
Not yet recruiting - verified May 2017


Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma


Condition:   Hepatitis C
Intervention:   Other: oral squamous cell carcinoma
Sponsor:   Cairo University
Not yet recruiting - verified April 2017


Hepatitis C Testing in VA Community-Based Outpatient Clinics


Condition:   Hepatitis C
Intervention:   Other: QI
Sponsor:   VA Office of Research and Development
Completed - verified October 2016


Study of Oral Treatments for Hepatitis C


Condition:   Chronic Hepatitis C
Interventions:   Drug: sofosbuvir/ledipasvir;   Drug: ombitasvir/paritaprevir/ritonavir (Phase 1 only);   Drug: elbasvir/grazoprevir;   Drug: Dasabuvir
Sponsors:   University of Florida;   Patient-Centered Outcomes Research Institute;   Merck Sharp & Dohme Corp.;   AbbVie
Recruiting - verified May 2017


Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil


Condition:   Hepatitis C Virus
Intervention:  
Sponsor:   Janssen-Cilag Ltd.
Completed - verified May 2017


Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients


Condition:   Hepatitis C
Intervention:   Drug: Alisporivir
Sponsor:   Debiopharm International SA
Completed - verified July 2016


An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection


Condition:   Hepatitis C Virus
Intervention:  
Sponsor:   Janssen-Cilag Ltd.
Completed - verified February 2017


Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection


Condition:   Hepatitis C
Intervention:   Drug: Harvoni
Sponsor:   Gilead Sciences
Active, not recruiting - verified February 2017


C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study


Condition:   Hepatitis C
Intervention:  
Sponsor:   Boston Children’s Hospital
Recruiting - verified March 2017


Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis


Condition:   Hepatitis C
Interventions:   Drug: Simeprivir (SMV);   Drug: Sofosbuvir (SOF);   Drug: Ribavirin (RBV)
Sponsors:   University of Colorado, Denver;   Janssen Scientific Affairs, LLC
Active, not recruiting - verified October 2016


Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients


Condition:   Hepatitis C
Intervention:  
Sponsors:   Prof. Dr. med. Jens Reimer;   Janssen-Cilag G.m.b.H
Recruiting - verified November 2016


Prevalence and Screening of Hepatitis C in Belgium in 2015


Condition:   Hepatitis C
Interventions:   Other: Questionnaire;   Procedure: HCV serology
Sponsor:   Brugmann University Hospital
Recruiting - verified July 2016


An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection


Condition:   Hepatitis C
Interventions:   Drug: Simeprevir;   Drug: Sofosbuvir
Sponsor:   Janssen-Cilag International NV
Completed - verified September 2016


Effect of Camel Milk on Chronic Hepatitis C


Condition:   Chronic Hepatitis C
Interventions:   Drug: Peginterferon, Ribavirin, camel milk;   Drug: Peginterferon, Ribavirin
Sponsor:   Mashhad University of Medical Sciences
Completed - verified July 2016


The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients


Condition:   Hepatitis C
Intervention:   Biological: Peginterferon lambda
Sponsor:   Nanogen Pharmaceutical Biotechnology Co., Ltd
Completed - verified February 2014


A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study


Condition:   Hepatitis C
Interventions:   Drug: ABT-450/ritonavir;   Drug: ABT-333;   Drug: ABT-267
Sponsor:   AbbVie (prior sponsor, Abbott)
Completed - verified October 2016


Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C


Condition:   Hepatitis C
Interventions:   Drug: Alisporivir;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
Sponsor:   Debiopharm International SA
Terminated - verified June 2016


HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network


Condition:   Hepatitis C
Intervention:  
Sponsors:   University of North Carolina, Chapel Hill;   University of Florida
Recruiting - verified May 2017


Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1


Condition:   Hepatitis C
Interventions:   Drug: Alisporivir;   Drug: Boceprevir;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
Sponsor:   Debiopharm International SA
Terminated - verified November 2016


Staged Phase I/II Hepatitis C Prophylactic Vaccine


Condition:   Hepatitis C
Interventions:   Biological: AdCh3NSmut1;   Biological: MVA-NSmut;   Other: Placebo
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting - verified April 5, 2017


Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants


Condition:   Hepatitis C
Interventions:   Drug: Alisporivir;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin;   Drug: ALV Placebo
Sponsor:   Debiopharm International SA
Completed - verified August 2016


A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)


Condition:   Hepatitis C, Chronic
Interventions:   Drug: Vaniprevir 600 mg b.i.d.;   Drug: Vaniprevir 300 mg b.i.d.;   Drug: Pegylated interferon;   Drug: Ribavirin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)


Condition:   Hepatitis C, Chronic
Interventions:   Drug: Vaniprevir;   Drug: Pegylated Interferon (Peg-IFN);   Drug: Ribavirin (RBV);   Drug: Placebo (PBO)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)


Condition:   Hepatitis C, Chronic
Interventions:   Biological: Peginterferon alfa-2b (PegIFN-2b);   Drug: Comparator: Stronger neo minophagen C (SNMC)
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified March 2017


Immune Response to Hepatitis C Virus


Condition:   Hepatitis C
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 24, 2015

Refine Your Search Advanced Search